Cart
sales@molnova.com
CCG-143140
CAS No. 891016-02-7
CCG-143140( ML-SI3 )
Catalog No. M24914 CAS No. 891016-02-7
CCG-143140 is a GLP-1 receptor inverse agonists.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 71 | In Stock |
|
| 2MG | 40 | In Stock |
|
| 5MG | 64 | In Stock |
|
| 10MG | 112 | In Stock |
|
| 25MG | 235 | In Stock |
|
| 50MG | 365 | In Stock |
|
| 100MG | 548 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCCG-143140
-
NoteResearch use only, not for human use.
-
Brief DescriptionCCG-143140 is a GLP-1 receptor inverse agonists.
-
DescriptionCCG-143140 is a GLP-1 receptor inverse agonists.
-
In VitroML-SI3 (10 μM) inhibits ML-SA1-evoked Ca2+ signals in HeLa cells.ML-SI3 (25-75 μM, 24h) disrupts tegumental integrity of adult schistosomes.ML-SI3 (10 μM) blocks Rapamycin (HY-10219)-evoked ITRPML1 in mimic of lysosomal lumen.ML-SI3 (3 μM, 6 h) abolishes the increase in both LC3II and p62 levels induced by hypoxia/reoxygenation (H/R) (4 h H/2 h R) in neonatal rat ventricular myocytes (NRVM).
-
In VivoML-SI3 (1.5 mg/kg, i.p., four times) attenuates I/R injury in mouse cardiomyocytes. Animal Model:Myocardial Ischemia/reperfusion (I/R) injury miceDosage:1.5 mg/kg Administration:Intraperitoneal injection (i.p.), four times before and during the in vivo I/R (ischemia 30 min and reperfusion 1 day)Result:Restored the blocked autophagic fux in the cardiomyocytes subjected to I/R.
-
SynonymsML-SI3
-
PathwayGPCR/G Protein
-
TargetGlucagon Receptor
-
RecptorGLP-1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number891016-02-7
-
Formula Weight429.58
-
Molecular FormulaC23H31N3O3S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (116.39 mM)
-
SMILESO=S(C1=CC=CC=C1)(NC2C(N3CCN(C4=CC=CC=C4OC)CC3)CCCC2)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Taspoglutide
Taspoglutide is a glucagon-like peptide-1(GLP-1) agonist for treatment of type 2 diabetes.
-
Glucagon-like peptid...
Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.Pancreatic hormone synthesized by post-translational processing of proglucagon. Unlike truncated forms of GLP-1, it has no effect on food intake in rats and does not enhance pancreatic insulin secretion.
-
LSN3318839
LSN3318839 is a potent and orally available glucagon-like peptide-1 receptor (GLP-1R) modulator.LSN3318839 enhances GLP-1R G-protein-coupled signaling and can be used to lower blood glucose.
